Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 3:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 251 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fed State Clear all

Conditions: Healthy Volunteer
Interventions: Icovamenib, Icovamenib HPMC; Drug
Lead sponsor: Biomea Fusion Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Depressive Disorder, Major
Interventions: LY2216684; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Healthy Adults
Interventions: EC5026 oral tablet, Placebo oral tablet; Drug · Other
Lead sponsor: EicOsis Human Health Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy
Interventions: omaveloxolone; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Major Depressive Disorder (MDD), Healthy Adult Volunteer
Interventions: Hot Cognitive Task, Cold cognitive tasks, Structural magnetic resonance imaging (sMRI), Magnetoencephalography imaging (MEG), four self-report forms per the requirement of the NIH Common Data Elements project, Four self-report measures to assess interpersonal functioning, Clinical assessments, ATHF; Behavioral · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 21 Years to 80 Years
Enrollment: 276 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Arlington, Texas • Dallas, Texas

Conditions: Infection, Human Immunodeficiency Virus
Interventions: DTG 50 mg, RPV 25 mg, DTG/RPV 50 mg/25 mg: Product Code AS, DTG/RPV 50 mg/25 mg: Product Code AM, DTG/RPV 50 mg/25 mg: Product Code AQ, DTG/RPV 50 mg/25 mg: Product Code AK, DTG/RPV 50 mg/25 mg: Product Code AR; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Renal Impairment, Tuberculosis
Interventions: PA-824; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 85 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 3
States / cities: Miami, Florida • St Louis, Missouri • Knoxville, Tennessee

Conditions: Concussion, mTBI, Post-Concussive Symptoms, Chronic Headache, Chronic Insomnia, Chronic Attention Disorder
Interventions: Neurofeedback (NFB); Procedure
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Infections, Human Immunodeficiency Virus and Herpesviridae, Infection, Human Immunodeficiency Virus
Interventions: GSK2248761 WBM Capsule, GSK2248761 WBM Tablet Formulation 1, GSK2248761 WBM Tablet Formulation 2, GSK2248761 WBM Tablet Formulation 3, GSK2248761 WBM Tablet; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Healthy
Interventions: PF-06291874 or Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Volunteer, Atopic Dermatitis, Hidradenitis Suppurativa
Interventions: KT-474/Placebo, KT-474; Drug
Lead sponsor: Kymera Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 154 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 14
States / cities: Phoenix, Arizona • Sun City West, Arizona • Boynton Beach, Florida + 8 more

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: GSK2838232 100 mg tablet, GSK2838232 50 mg capsule, Ritonavir 100 mg tablets, Placebo for GSK2838232 tablets; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: Itraconazole; Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: HIV Infections
Interventions: JULUCA (Dolutegravir and Rilpivirine) 50mg/25mg FDC tablet; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Glendale, California

Conditions: Effect of Food
Interventions: Oral WCK2349, IV WCK771; Drug
Lead sponsor: Wockhardt; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Volunteers
Interventions: MF-300 SAD, Placebo, MF-300 Food Effect, MF-300 MAD; Drug
Lead sponsor: Epirium Bio Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Marlton, New Jersey • Austin, Texas

Conditions: Healthy
Interventions: PF-06291874, placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Opioid Dependence, Opioid Use Disorder (OUD)
Interventions: VK4-116, Placebo; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Hypertension
Interventions: COREG CR and lisinopril (FDC); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Prostatic Hyperplasia
Interventions: FDC capsule of dutasteride and tamsulosin, Dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: NKTR118 Formulation 1, NKTR118 Formulation 2, NKTR118 Formulation 3, NKTR118 Formulation 1a, NKTR118 Formulation 3a; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy Adults
Interventions: sitravatinib; Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy Volunteers
Interventions: TS-134, Placebo; Drug
Lead sponsor: Taisho Pharmaceutical R&D Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Glendale, California

Conditions: Gout, Food-drug Interaction
Interventions: ABP-671; Drug
Lead sponsor: Atom Therapeutics Co., Ltd; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Food Effect Study in Healthy Volunteers

A Study to Evaluate the Effect of Food on LY2216684

Safety, Tolerability, Pharmacokinetics and Food Effects of Oral EC5026 in Healthy Subjects

A Pharmacokinetic Study of Omaveloxolone in Healthy Volunteers

Emotional Cognition: Establishing Constructs and Neural-Behavioral Mechanisms in Older Adults With Depression

Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects

Single-Dose Study to Evaluate the PKs of Pretomanid in Participants With Renal Impairment Compared to Participants With Normal Renal Function

Neurofeedback Impact on Veterans With mTBI

A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435

A Single Dose Study Of PF-06291874 In Healthy Adult Subjects

A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)

A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir

Study to Assess Blood Levels of Itraconazole During a Two-Week Period

Study to Evaluate Pharmacokinetics, Safety and Tolerability of Dolutegravir and Rilpivirine (JULUCA™) 50 Milligram (mg)/25 mg Tablets in Healthy Subjects of Japanese Descent

Phase I, Open Label,Crossover Food-Effect and Absolute Bioavailability Study of WCK2349 and WCK771 in Healthy Adult Human Volunteers

Single and Multiple Ascending Dosing Administration of MF-300 in Healthy Participants

Single Dose Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 In Healthy Adult Subjects

VK4-116 Phase I Study With Food-Effect

Study to Examine the Effect of Food on the Pharmacokinetics of the Fixed Dose Combination of COREG CR and Lisinopril.

Bioavailability Study of Fixed Dose Combination (FDC) Dutasteride and Tamsulosin Hydrochloride (HCl) Relative to One Dutasteride and One Tamsulosin HCl Tablet in Healthy Male Subjects

Assessment of Relative Bioavailability of NKTR-118 in Three Formulations in Healthy Subjects

A Study to Explore the Effect of Food Before a Single Dose of Sitravatinib

Safety, Tolerability and Pharmacokinetics of 14-day Multiple Dose Titrations of TS-134 in Healthy Volunteers

Study to Investigate the Effects of Food on Relative Bioavailability of ABP-671 Tablets in Healthy Subjects